Physician profile
Laurence M Petty
NPI 1265655757
$140,019.98
in general payments reported to CMS, 2019-2025
30 companies · $8,797 in 2025
The $8,797 reported for 2025 was more than what 99% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $8,097 · 2021: $10K · 2022: $15K · 2023: $51K · 2024: $34K · 2025: $8,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Travel and Lodging: $15K · Food and Beverage: $10K · Consulting Fee: $3,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,292.00 |
| Travel and Lodging | $15,283.43 |
| Food and Beverage | $10,277.11 |
| Consulting Fee | $3,900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $64,105.60 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Otsuka America Pharmaceutical, INC. | $24,511.02 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $21,906.74 | 2019-2023 | Trulicity |
| Urovant Sciences INC | $11,899.33 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $5,581.22 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $1,695.66 | 2019-2025 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $1,298.45 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,240.13 | 2021-2024 | Farxiga, Lokelma |
| Sumitomo Pharma America, INC. | $1,236.54 | 2023-2024 | Gemtesa, Aptiom |
| Smith+Nephew, INC. | $1,091.05 | 2019-2025 | Collagenase Santyl, Versajet, Iodosorb Ointment 40g USA |
| Teva Pharmaceuticals USA, INC. | $1,011.83 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Sunovion Pharmaceuticals INC. | $869.25 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $611.61 | 2022-2024 | |
| Sk Life Science, INC. | $487.29 | 2020-2023 | Xcopri |
| Greenwich Biosciences, INC. | $483.51 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $470.18 | 2021-2022 | |
| Astellas Pharma US INC | $347.65 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $275.19 | 2019-2021 | |
| Argenx US, INC. | $250.36 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $198.39 | 2024-2025 | Rexulti |
| Eisai INC. | $120.12 | 2023 | |
| Cipher Pharmaceuticals US LLC | $90.51 | 2025 | Spinosad, Natroba |
| Alpha Cognition USA, INC. | $51.72 | 2025 | Zunveyl |
| Hill-Rom Company, INC | $37.87 | 2021 | |
| Janssen Pharmaceuticals, INC | $35.44 | 2019 | |
| Lundbeck LLC | $33.52 | 2023 | Rexulti |
| Vivus LLC | $24.13 | 2023 | Qsymia |
| Catalyst Pharmaceuticals, INC. | $21.74 | 2023 | Fycompa |
| Sanofi-Aventis U.S. LLC | $20.77 | 2019 | |
| Kyowa Kirin, INC. | $13.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurence Petty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.